Deutsch English Français

Contact

EP3275441

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3275441

EP3275441 - EXTERNAL MEDICINE FOR DIFFUSE PLEXIFORM NEUROFIBROMA [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 18.06.2021 Database last updated on 21.03.2025
Former	The patent has been granted Status updated on 10.07.2020
Former	Grant of patent is intended Status updated on 27.02.2020
Former	Request for examination was made Status updated on 29.12.2017
Former	The international publication has been made Status updated on 12.10.2017
Most recent event Tooltip	13.09.2024	Lapse of the patent in a contracting state New state(s): MT	published on 16.10.2024 [2024/42]
Applicant(s)	For all designated states Osaka University 1-1 Yamadaoka Suita-shi, Osaka 565-0871 / JP
	[2020/33]
Former [2018/05]	For all designated states Osaka University 1-1 Yamadaoka Suita-shi, Osaka 565-0871 / JP
Inventor(s)	01 / KANEDA, Mari c/o OSAKA UNIVERSITY 1-1 Yamadaoka Suita-shi Osaka 565-0871 / JP
	02 / KATAYAMA, Ichiro c/o OSAKA UNIVERSITY 1-1 Yamadaoka Suita-shi Osaka 565-0871 / JP
	[2018/05]
Representative(s)	TBK Bavariaring 4-6 80336 München / DE
	[2020/33]
Former [2018/05]	Cabinet Plasseraud 66, rue de la Chaussée d'Antin 75440 Paris Cedex 09 / FR
Application number, filing date	16768422.4	09.03.2016
	[2018/05]
	WO2016JP57330
Priority number, date	JP20150059041	23.03.2015 Original published format: JP 2015059041
	[2018/05]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2016152519
	Date:	29.09.2016
	Language:	JA
	[2016/39]
	Type:	A1 Application with search report
	No.:	EP3275441
	Date:	31.01.2018
	Language:	EN
	[2018/05]
	Type:	B1 Patent specification
	No.:	EP3275441
	Date:	12.08.2020
	Language:	EN
	[2020/33]
Search report(s)	International search report - published on:	JP	29.09.2016
	(Supplementary) European search report - dispatched on:	EP	13.12.2018
Classification	IPC:	A61K31/436, A61K9/06, A61K47/10, A61P21/00, A61P25/00	[2018/05]
	CPC:	A61K31/436 (EP,US); A61K47/10 (EP,US); A61K9/06 (EP,US); A61P35/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/05]
Extension states	BA	Not yet paid
	ME	Not yet paid
Validation states	MA	Not yet paid
	MD	Not yet paid
Title	German:	EXTERNES MEDIKAMENT FÜR DIFFUSES PLEXIFORMES NEUROFIBROM	[2018/05]
	English:	EXTERNAL MEDICINE FOR DIFFUSE PLEXIFORM NEUROFIBROMA	[2018/05]
	French:	MÉDICAMENT À USAGE EXTERNE POUR LE NEUROFIBROME PLEXIFORME DIFFUS	[2018/05]
Entry into regional phase	11.10.2017	Translation filed
	11.10.2017	National basic fee paid
	11.10.2017	Search fee paid
	11.10.2017	Designation fee(s) paid
	11.10.2017	Examination fee paid
Examination procedure	11.10.2017	Examination requested [2018/05]
	11.10.2017	Date on which the examining division has become responsible
	10.07.2019	Amendment by applicant (claims and/or description)
	28.02.2020	Communication of intention to grant the patent
	06.07.2020	Fee for grant paid
	06.07.2020	Fee for publishing/printing paid
	06.07.2020	Receipt of the translation of the claim(s)
Opposition(s)	14.05.2021	No opposition filed within time limit [2021/29]
Fees paid	Renewal fee
	13.03.2018	Renewal fee patent year 03
	27.03.2019	Renewal fee patent year 04
	20.03.2020	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	09.03.2016
	AL	12.08.2020
	AT	12.08.2020
	CY	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	MK	12.08.2020
	MT	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	PT	14.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
	[2024/42]
Former [2024/22]	HU	09.03.2016
	AL	12.08.2020
	AT	12.08.2020
	CY	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	MK	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	PT	14.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2023/33]	HU	09.03.2016
	AL	12.08.2020
	AT	12.08.2020
	CY	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	PT	14.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2023/30]	AL	12.08.2020
	AT	12.08.2020
	CY	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	PT	14.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2023/20]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	PT	14.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2023/10]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	GB	09.03.2021
	IE	09.03.2021
	IT	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2022/34]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	GB	09.03.2021
	IE	09.03.2021
	LU	09.03.2021
	ES	10.03.2021
	BE	31.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2022/11]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	GB	09.03.2021
	IE	09.03.2021
	LU	09.03.2021
	CH	31.03.2021
	FR	31.03.2021
	LI	31.03.2021
Former [2022/08]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	GB	09.03.2021
	IE	09.03.2021
	LU	09.03.2021
	FR	31.03.2021
Former [2022/07]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
	IE	09.03.2021
Former [2021/45]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	MC	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/36]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SI	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/28]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SK	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/25]	AL	12.08.2020
	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/23]	AT	12.08.2020
	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/22]	CZ	12.08.2020
	DK	12.08.2020
	EE	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RO	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	SM	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/21]	DK	12.08.2020
	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/12]	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	NL	12.08.2020
	PL	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/10]	FI	12.08.2020
	HR	12.08.2020
	LT	12.08.2020
	LV	12.08.2020
	PL	12.08.2020
	RS	12.08.2020
	SE	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
	IS	12.12.2020
Former [2021/09]	FI	12.08.2020
	LT	12.08.2020
	SE	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
	GR	13.11.2020
Former [2021/08]	FI	12.08.2020
	LT	12.08.2020
	SE	12.08.2020
	BG	12.11.2020
	NO	12.11.2020
Former [2021/07]	FI	12.08.2020
	LT	12.08.2020
	NO	12.11.2020
Documents cited:	Search	[Y]WO2006083979 (NEXGENIX PHARMACEUTICALS L L C [US], et al) [Y] 1-8 * claims 20,35,38 *;
		[Y] - C. HUA ET AL, "Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas", PEDIATRICS, (20140526), vol. 133, no. 6, doi:10.1542/peds.2013-1224, ISSN 0031-4005, pages e1792 - e1797, XP055514473 [Y] 1-8 * the whole document * DOI: http://dx.doi.org/10.1542/peds.2013-1224
		[Y] - B. WEISS ET AL, "Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study", NEURO-ONCOLOGY, US, (20141014), vol. 17, no. 4, doi:10.1093/neuonc/nou235, ISSN 1522-8517, pages 596 - 603, XP055514475 [Y] 1-8 * the whole document * DOI: http://dx.doi.org/10.1093/neuonc/nou235
	International search	[Y]WO2006071966 (BRIGHAM & WOMENS HOSPITAL [US], et al) [Y] 1-5 * , claims; page 4, B. & US 2006/0160837 A1 *;
		[Y]JP2009525294 (Novartis AG.) [Y] 1-5 * , claims; paragraph [0007] & US 2010/0305150 A1 claims; paragraph [0008] & GB 602123 A & WO 2007/088034 A2 & EP 1983984 A & CA 2637255 A & KR 10-2008-0090493 A & CN 101378751 A & RU 2008135131 A & AU 2007211613 A & KR 10-2014-0016439 A & CN 104000818 A & AU 2011205053 A *;
		[Y]WO2012105521 (UNIV OSAKA [JP], et al) [Y] 1-5 * , claims; paragraphs [0010] to [0011], [0019], [0030], [0036], [0076] to [0078]; examples & US 2013/0317053 A1 claims; paragraphs [0020] to [0021], [0029], [0071], [0077], [0117] to [0119]; examples & EP 2671583 A1 & AU 2012211809 A & CA 2825786 A *;
		[Y] - YUICHI YOSHIDA et al., "Bohansho Idensei Shikkan Saizensen; Shindan, Chiryo to Taio Shinkei Sen'ishusho 1-gata (NF1) no Shindan to Chiryo", Japanese Journal of Dermatology, (20120000), vol. 122, no. 13, pages 3189 - 3191, XP 009506207 [Y] 1-5 * , Hajimeni, 2., 4., fig. 1, table 1 *
		[Y] - TOSHIHIRO ITO, "Origin of Melanin Containing Cells of Diffuse Plexiform Neurofibroma in Patients with Neurofibromatosis 1", Jikeikai Medical Journal, (20020000), vol. 117, no. 4, pages 277 - 284, XP055492186 [Y] 1-5 * , abstract, I. *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.32; 34p